Tango Therapeutics Q2 net loss widens to $55.3 million; collaboration revenue is $0
Tango Therapeutics reported a second-quarter 2026 net loss of $55.3 million, or $0.37 per share, up from $38.9 million, or $0.35 per share, a year earlier. Collaboration revenue was $0 versus $3.2 million, and operating expenses rose as research and administrative spending increased, which widens the gap shareholders are funding while the company prepares vopimetostat for late-stage development. The company reported $1.0 billion in cash, cash equivalents and marketable securities as of June 30, 2026, which it expects to fund its current operating plan.
Key points
- Q2 2026 net loss of $55.3 million ($0.37 per share) vs. $38.9 million ($0.35 per share) in Q2 2025
- Collaboration revenue was $0 in Q2 2026 vs. $3.2 million in Q2 2025; all remaining Gilead deferred revenue was recognized in 2025
- G&A expenses were $22.6 million vs. $11.3 million, and R&D expenses were $37.2 million vs. $32.8 million
- Cash, cash equivalents and marketable securities totaled $1.0 billion as of June 30, 2026
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.